Anti-angiogenic agent-associated adrenal insufficiency in immune checkpoint inhibitors-treated patients

Eur J Cancer. 2021 Nov:157:358-360. doi: 10.1016/j.ejca.2021.08.038. Epub 2021 Sep 23.

Authors

Qixiang Guo¹, Wenchao Lu¹, Ximu Sun², Zhixia Zhao³, Lihong Liu⁴

Affiliations

¹ Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
² Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
³ Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Electronic address: zhixia.1002@163.com.
⁴ Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China. Electronic address: liulihong@bjcyh.com.

PMID: 34563990
DOI: 10.1016/j.ejca.2021.08.038

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Adrenal Insufficiency / chemically induced
Adrenal Insufficiency / diagnosis
Adrenal Insufficiency / epidemiology*
Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / adverse effects*
Angiogenesis Inhibitors / pharmacokinetics
Anilides / administration & dosage
Anilides / adverse effects
Anilides / pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
Drug Synergism
Humans
Immune Checkpoint Inhibitors / administration & dosage
Immune Checkpoint Inhibitors / adverse effects*
Immune Checkpoint Inhibitors / pharmacokinetics
Neoplasms / drug therapy*
Nivolumab / administration & dosage
Nivolumab / adverse effects
Nivolumab / pharmacokinetics
Pyridines / administration & dosage
Pyridines / adverse effects
Pyridines / pharmacokinetics
Risk Assessment / statistics & numerical data

Substances

Angiogenesis Inhibitors
Anilides
Immune Checkpoint Inhibitors
Pyridines
cabozantinib
Nivolumab